We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
-12.87%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$266M
AUM Growth
-$36M
Cap. Flow
+$4.9M
Cap. Flow %
1.84%
Top 10 Hldgs %
54.75%
Holding
84
New
18
Increased
15
Reduced
8
Closed
22

Top Buys

Rank Stock Value
1
OGN icon
Organon & Co
OGN
+$20.1M
2
COR icon
Cencora
COR
+$15.3M
3
BCYC
Bicycle Therapeutics
BCYC
+$13.4M
4
HCA icon
HCA Healthcare
HCA
+$13.3M
5
MDT icon
Medtronic
MDT
+$8.11M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$16M
2
SNY icon
Sanofi
SNY
+$15.4M
3
LH icon
Labcorp
LH
+$13M
4
MCK icon
McKesson
MCK
+$10.6M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$9.1M

Sector Composition

Rank Sector Weight
1 Healthcare 84.08%
2 Financials 8.53%
3 Consumer Staples 1.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MODD icon
26
Modular Medical
MODD
$12.9M
$2.98M 1.12%
+19,145
New +$2.62M
VKTX icon
27
Viking Therapeutics
VKTX
$3.7B
$2.89M 1.09%
999,829
– –
RXDX
28
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$2.87M 1.08%
+101,600
New +$2.94M
EUCRU
29
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.49M 0.94%
248,674
– –
OBIO icon
30
Orchestra BioMed
OBIO
$238M
$2.49M 0.94%
250,000
– –
SYRE icon
31
Spyre Therapeutics
SYRE
$8.54B
$2.36M 0.89%
186,741
+151,897
+436% +$5.32M
AFMD
32
DELISTED
Affimed
AFMD
$2.27M 0.85%
82,107
+17,741
+28% +$607K
MRUS
33
DELISTED
Merus
MRUS
$1.99M 0.75%
87,953
-2,047
-2% -$42.7K
CBAY
34
DELISTED
Cymabay Therapeutics
CBAY
$1.64M 0.62%
555,610
-6,729
-1% -$16.1K
DTIL icon
35
Precision BioSciences
DTIL
$180M
$1.61M 0.61%
+33,633
New +$1.97M
MBRX icon
36
Moleculin Biotech
MBRX
$2.83M
$1.5M 0.56%
2,765
-10
-0.4% -$5.82K
RCOR
37
DELISTED
Renovacor, Inc.
RCOR
$1.49M 0.56%
735,908
– –
SVRA icon
38
Savara
SVRA
$1.12B
$1.3M 0.49%
856,428
+140,166
+20% +$184K
ANIP icon
39
ANI Pharmaceuticals
ANIP
$1.8B
$1.19M 0.45%
40,000
– –
ALBO
40
DELISTED
Albireo Pharma Inc
ALBO
$1.16M 0.44%
58,556
-85,990
-59% -$2.27M
TYRA icon
41
Tyra Biosciences
TYRA
$1.9B
$1.09M 0.41%
152,159
+41,126
+37% +$327K
PRDS
42
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$969K 0.36%
315,564
– –
NBSE
43
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$952K 0.36%
45,322
– –
ISO
44
DELISTED
IsoPlexis Corporation Common Stock
ISO
$879K 0.33%
407,102
– –
ISEE
45
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$831K 0.31%
+86,400
New +$1.08M
FUSN
46
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$649K 0.24%
260,448
+685
+0.3% +$3.15K
ASLN
47
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$629K 0.24%
31,769
– –
NXTC icon
48
NextCure
NXTC
$16.8M
$611K 0.23%
10,833
– –
CNTB
49
Connect Biopharma Holdings
CNTB
$127M
$520K 0.2%
597,678
– –
ELEV
50
DELISTED
Elevation Oncology
ELEV
$504K 0.19%
359,731
– –
1
2
3 4

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Sio Capital Management held 84 positions worth $266M, down 12% from $302M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Sio Capital Management's Q2 2022 filing shows 18 new, 15 increased, 8 reduced and 22 closed positions. Its largest new stake was Organon & Co: 574,855 shares worth $19.4M. The largest sale was Merck, an estimated $16M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 74% a quarter earlier, followed by Financials and Consumer Staples.

  • Sio Capital Management's largest Q2 2022 buy was Organon & Co: 574,855 shares worth $19.4M.
  • Sio Capital Management added most to Cencora in Q2 2022, an estimated $15.3M increase.
  • Sio Capital Management's biggest Q2 2022 reduction was Cigna, cutting an estimated $3.81M.
  • Sio Capital Management fully exited Merck in Q2 2022, selling an estimated $16M.
  • Sio Capital Management's ten largest holdings make up 55% of its $266M portfolio in Q2 2022.
  • Sio Capital Management opened 18 new positions and closed 22 in Q2 2022.
  • Sio Capital Management's portfolio value fell 12% quarter-over-quarter to $266M.

Based on Sio Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.